Clinical trial
A Randomized, Double-blind, Placebo-controlled, Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) Trial of Multiple Ascending Fixed Doses of SAM-531 in Subjects With Mild to Moderate Alzheimer's Disease.
NCT00481520 is registered in ClinicalTrials.gov with Wyeth is now a wholly owned subsidiary of Pfizer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled, Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) Trial of Multiple Ascending Fixed Doses of SAM-531 in Subjects With Mild to Moderate Alzheimer's Disease.
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- June 30, 2007
- Completion date
- January 31, 2008
- Enrollment
- 72 (estimated)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.